ArticleEuropean journal of rheumatology2025
Decade-Long Study on Phenotype and Prognosis of Lupus Myelitis (LM) in Systemic Lupus Erythematosus (SLE): Insights from a Single-Centre in India.
Article in European journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic lupus erythematosus (SLE)-associated myelitis or lupus myelitis (LM), one of the twelve neuropsychiatric lupus (NPSLE) syndromes, is a rare but severe complication of lupus. In this study, we observed the clinical and imaging profiles of LM patients to assess long-term outcomes. Methods: This was a retrospective study; data of LM with follow-up were extracted from the lupus registry in the last 15 years (2007-2022). Clinically, they were divided as grey matter myelitis (GMM) versus white matter myelitis (WMM). Disease activity was assessed by the SLE Disease Activity Index (SLEDAI-2K) & outcome by death, recurrence, and modified Rankin Score (MRS). Survival analysis was performed using the Kaplan-Meier (KM) and Weibull survival probability tests. Results: 38 patients were included out of 1700 lupus patients over the last 15 years. Among them, 26 patients presented with GMM, and 12 presented with WMM. Patients with GMM had significantly higher SLEDAI and MRS at discharge compared to WMM patients. (P-value-.021 and .08, respec-tively). White matter myelitis patients had higher levels of anti-cardiolipin antibodies. (P-.005) MRI-positive myelitis was associated with higher dsDNA levels compared to MRI-negative myelitis (P-.03), but there was no significant difference in disease activity or outcome. The Weibull probability plot indicated poor survival status in GMM. Conclusion: The prevalence of LM in our cohort is around 2%. Grey matter myelitis is associated with more active disease and significant disability. Survival analysis revealed a poor outcome for GMM in this study.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.